VERAXA Biotech shares are trading lower. The company announced it has generated new in vitro proof-of-concept data validating its BiTAC-ADC technology platform.

Benzinga Newsdesk www.benzinga.com Neutral 40.8%

Neg 0% Neu 40.8% Pos 0%

Comments

No comments yet. Be the first!